EMA launches public consultation on ESVAC strategy for 2016-2020. The draft ‘Vision and Strategy of the European Surveillance of Veterinary Antimicrobial Consumption (ESVAC)’, for 2016-2020, published today for a three-month public consultation and the main objective is to strengthen this prospective by further sustaining the compilation and study of robust data.
Accessibility of reliable and intent data on the use of antimicrobials in animals is necessary to update European countries in establishing efficient policies to fight antimicrobial resistance.
Every year, the European Medicines Agency (EMA) publishes a report with sales figures of antimicrobials in animals collected by the ESVAC activity.
From 2016-20, ESVAC will keep on collecting and publishing overall sales data from as many EU/EEA countries as possible. With the addition of data from Croatia, Romania and Switzerland in the report to be published in 2016, the purpose to comprise data from all EEA countries is already close to being achieved.
ESVAC has an objective to bring together the best available European proficiency and capability to promote coordination in the methodologies used to collect and evaluate data on utilization of antimicrobials in animals. It will also give guidance to sustain the collection of data on the use of antimicrobials per species, with an explicit focus on the three major food-producing species (pigs, poultry and cattle).
ESVAC is establishing Defined Daily Doses for animals (DDDvet) and Defined Course Doses for animals (DCDvet) for more precise estimation of the disclosure to antimicrobials by animal species and thus strengthen the strength of the analysis of the data.
This will also helpful for policymakers in making evidence-based policies to reduce the risks from use of antimicrobials based on data on the definite use of antimicrobials in animals.
Antimicrobial resistance is progressively main and vital apprehension for both human and animal health. EMA works with its EU and international partners on a number of initiatives intended to limit the growth of resistance. EMA also works to maintain the expansion of new treatments and to support responsible use of antimicrobials.
7th April 2016
http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2016/04/news_detail_002507.jsp&mid=WC0b01ac058004d5c1